CME at Panchkula on Clinical Utility of hsTropI & Pivka-II

Topics:

• Clinical utility of hsTnI beyond diagnosis
• A novel bio-marker in hepatocellular carcinoma diagnosis (HCC)

Abstract:

Clinical Utility of hs Trop i Beyond Diagnosis:

High-sensitivity troponin I (hsTnI) is a cardiac troponin I that is released into the bloodstream in response to liver damage. It is a more sensitive and specific marker of liver injury than traditional markers such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT).

In addition to its diagnostic utility in liver diseases, hsTnI has also been shown to be useful for:

• Prognosis: hsTnI levels on admission are associated with the severity of liver disease and mortality.
• Risk stratification: hsTnI levels can be used to risk stratify patients with liver disease and identify those at high risk of complications.
• Monitoring response to treatment: hsTnI levels can be used to monitor the response to treatment for liver diseases and to detect early signs of recurrence.

A Novel Biomarker in Hepatocellular Carcinoma Diagnosis (HCC)

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is associated with a poor prognosis. Early diagnosis and treatment are essential for improving patient outcomes. A novel biomarker called glypican-3 (GPC3) has been shown to be promising for the diagnosis of HCC. GPC3 is a protein that is overexpressed in HCC cells. It is a more specific marker of HCC than other liver cancer markers, such as alpha-fetoprotein (AFP).

GPC3 can be used to diagnose HCC, especially in patients with low AFP levels. It can also be used to monitor the response to treatment and to detect recurrence of HCC.

The CME program at Panchkula will provide an overview of the clinical utility of hsTnI beyond diagnosis and a novel biomarker in hepatocellular carcinoma diagnosis (HCC). The speakers will discuss the latest evidence on the use of these biomarkers and will share their own experience in using them in clinical practice.